ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management
Gastroenterology
Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP
Rhinology
Prof. Joaquim Mullol reports on biologic improvements in sense of smell and nasal congestion in patients with and without a history of endoscopic sinus surgery.
IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
Prof. Eugenio De Corso describes the importance of real-world evidence for understanding the prospects of remission and the emerging evidence of biologic effectiveness for patients with CRSwNP.
An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Eosinophilic Esophagitis (EoE) Interactive Patient Case
Gastroenterology
Learn about the guidelines for diagnosis, treatment options, and criteria for treatment response in EoE through the journey of a hypothetical EoE patient
Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness
Rhinology
Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
